Efficacy of topical tofacitinib, a Janus kinase inhibitor, in the treatment of plaque psoriasis

被引：6
|
作者：
Bagherani, Nooshin [1 ]
Smoller, Bruce R. [2 ]
机构：
[1] Dr Nooshin Bagherans Off, Khoramshahr, Khuzestan Provi, Iran
[2] Univ Rochester, Sch Med & Dent, Dept Dermatol, Dept Pathol, Rochester, NY 14642 USA
来源：
DERMATOLOGIC THERAPY | 2017年 / 30卷 / 03期
关键词：
psoriasis; tofacitinib; treatment; CLINICAL-TRIAL;
D O I：
10.1111/dth.12467
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Long-term safety data for tofacitinib, an oral Janus kinase inhibitor, for the treatment for psoriasis
    Lloyd-Lavery, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (04) : 815 - 816
  • [12] Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment
    Strober, B.
    Buonanno, M.
    Clark, J. D.
    Kawabata, T.
    Tan, H.
    Wolk, R.
    Valdez, H.
    Langley, R. G.
    Harness, J.
    Menter, A.
    Papp, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2013, 169 (05) : 992 - 999
  • [13] The Janus-Kinase-Inhibitor Tofacitinib
    Krome, Susanne
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2013, 51 (01): : 7 - 7
  • [14] Safety of tofacitinib, an oral Janus kinase inhibitor: integrated data analysis from the global chronic plaque psoriasis clinical trials
    Wolk, R.
    Langley, R.
    Cohen, A.
    Foley, P.
    Griffiths, C.
    Lebwohl, M.
    Leonardi, C.
    Winthrop, K.
    Proulx, J.
    Rottinghaus, S.
    Thompson, J.
    Tatulych, S.
    Mallbris, L.
    Swanson, R.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 72 - 73
  • [15] SAFETY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR: INTEGRATED DATA ANALYSIS FROM THE GLOBAL CHRONIC PLAQUE PSORIASIS CLINICAL TRIALS
    Langley, R. G. B.
    Cohen, A. D.
    Foley, P.
    Griffiths, C. E. M.
    Lebwohl, M.
    Leonardi, C.
    Winthrop, K.
    Proulx, J.
    Rottinghaus, S. T.
    Wolk, R.
    Thompson, J. R.
    Tatulych, S.
    Mallbris, L.
    Swanson, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 253 - 253
  • [16] Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials
    Papp, K. A.
    Menter, M. A.
    Abe, M.
    Elewski, B.
    Feldman, S. R.
    Gottlieb, A. B.
    Langley, R.
    Luger, T.
    Thaci, D.
    Buonanno, M.
    Gupta, P.
    Proulx, J.
    Lan, S.
    Wolk, R.
    BRITISH JOURNAL OF DERMATOLOGY, 2015, 173 (04) : 949 - 961
  • [17] Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib
    Rothstein, Brooke
    Joshipura, Deep
    Saraiya, Ami
    Abdat, Rana
    Ashkar, Huda
    Turkowski, Yana
    Sheth, Vaneeta
    Huang, Victor
    Au, Shiu Chung
    Kachuk, Courtney
    Dumont, Nicole
    Gottlieb, Alice B.
    Rosmarin, David
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : 1054 - +
  • [18] Treatment of vitiligo with topical janus kinase inhibitor ruxolitinib
    Rothstein, B.
    Joshipura, D.
    Saraiya, A.
    Abdat, R.
    Ashkar, H.
    Turkowski, Y.
    Sheth, V.
    Huang, V.
    Au, S. Chung
    Kachuk, C.
    Dumont, N.
    Gottlieb, A. B.
    Rosmarin, D.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (05) : S132 - S132
  • [19] Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients
    Liu, Lucy Y.
    Craiglow, Brittany G.
    King, Brett A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 78 (02) : 403 - 404
  • [20] Tofacitinib: The First Janus Kinase (JAK) Inhibitor for the Treatment of Rheumatoid Arthritis
    Vyas, Deepti
    O'Dell, Kate M.
    Bandy, Jason L.
    Boyce, Eric G.
    ANNALS OF PHARMACOTHERAPY, 2013, 47 (11) : 1524 - 1531
12345